Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | $(2,293) | $(11,827) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Depreciation and amortization | 26,132 | 20,383 |
| Amortization of premium/discount on marketable securities | (192) | (1,074) |
| Change in fair value of contingent consideration | 2,391 | 7,660 |
| Realized loss (gain) from sale of marketable securities | (21) | 9 |
| Share-based compensation expense | 8,480 | 8,068 |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's D&A?
- Supernus Pharmaceuticals (SUPN) reported D&A of $26.13M in Q1 2026.
- How has Supernus Pharmaceuticals's D&A changed year-over-year?
- Supernus Pharmaceuticals's D&A increased by 28.2% year-over-year, from $20.38M to $26.13M.
- What is the long-term trend for Supernus Pharmaceuticals's D&A?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's D&A has grown at a 29.5% compound annual growth rate (CAGR), from $32.6M to $91.56M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Supernus Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude